In general, mean tumor absorbed doses reported here for the first dose cycle were in line with those described previously of 3.20–5.80 mGy/MBq for [177Lu]Lu-PSMA-I&T [26–29] and 1.68–15.7 mGy/MBq for [177Lu]Lu-PSMA-617 as reviewed in [9] with high variability between individual lesions in each of the studies. This evidence concerns the gene FOLH1 and neoplasm.